NCT00002574View on ClinicalTrials.gov

Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

87

Participants

Timeline

Start Date

September 30, 1994

Primary Completion Date

June 30, 2001

Conditions

Leukemia

Interventions

BIOLOGICAL

recombinant interferon alfa

DRUG

omacetaxine mepesuccinate

Trial Locations (2)

77030

University of Texas - MD Anderson Cancer Center, Houston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH